Curis shares surge 16.37% after-hours as company announces clinical data presentations for emavusertib at SNO meeting.

Curis, Inc. (NASDAQ: CRIS) surged 16.37% in after-hours trading following announcements of multiple data presentations on emavusertib, its IRAK4 inhibitor, at the 30th Annual Society for Neuro-Oncology (SNO) Meeting from November 21–23, 2025. The presentations include clinical updates on emavusertib combined with BTK inhibitors in treating relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL/SCNSL), as well as preclinical findings on its potential in melanoma brain metastases. These updates, featuring poster and oral sessions by leading researchers, highlight progress in pivotal trials and could bolster investor confidence in the drug’s therapeutic potential. Unrelated news about “Curis Lifesciences Ltd.,” an Indian pharmaceutical company with an IPO on NSE SME, was excluded as it pertains to a distinct entity. The positive reaction aligns with the biotech sector’s focus on clinical milestones and data visibility at high-profile conferences.